In the second obesity trial, SURMOUNT-2, tirzepatide prevails.

Published Date: 29 Apr 2023

According to Lilly's top-line results from the SURMOUNT-2 trial, which was intended to test the effectiveness of weight loss medications, the "twincretin" tirzepatide (Mounjaro) met its primary endpoints when compared to a placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot